Top 25 stocks in NSE 500 which gained over 20% in August
New Delhi, Sep 2 (IANS) Brightcom Group is the worst performing stock in the NSE 500 in the month of August-- down 32 per cent.As per a research by BOB Economics Research, Tanla Platforms...
Strong Buy
or
Jubilant Pharmova News & Analysis
-
-
L&T Finance, Tata Communications, Bank of Maharashtra to Release Q1 Today
By Malvika Gurung Investing.com -- The leading non-banking financial company (NBFC) L&T Finance Holdings (NS:LTFH) is set to release its financial earnings for the quarter ended June 30,...
-
Jubilant Pharmova Tanks 11% on USFDA Inspection Update, Glum Q4 Earnings
By Malvika Gurung Investing.com -- Shares of the pharmaceutical company Jubilant Pharmova (NS:JUBA) were under focus on Tuesday as they tanked 11% in the session to Rs 322.9 apiece, defying...
-
Pharma stock jumps 14% after the Canadian govt. provides loan facility
The shares of Jubilant Pharmova (NS:JUBA) Ltd. rallied as much as 14.45% to Rs 318 on Friday after the company announced that the Canadian government has provided an additional loan...
-
Jubilant Pharmova earnings miss, Revenue beats in Q2
Investing.com - Jubilant Pharmova (NS:JUBA) reported on Thursday second quarter {{erl-18246||earnings that missed analysts' forecasts and revenue that topped expectations. Jubilant...
-
Stock Overview: Stocks That Swung Up to 20% on Monday
By Malvika Gurung Investing.com -- Jubilant Pharmova (NS:JUBA) The Rakesh Jhunjhunwala-backed pharmaceutical stock rallied up to 13% and ended 10.4% higher on Monday. The stocks zoomed...
-
Rakesh Jhunjhuwala-Led Pharma Stock Rallies Soars 13% on Monday: Details
By Malvika Gurung Investing.com -- Shares of the pharmaceutical company Jubilant Pharmova (NS:JUBA) rallied up to 13% on Monday and ended the session 10.4% higher at Rs 449.65 apiece. The...
-
3 Mid-Cap Stocks that Can Go Up between 26%-38%
By Aditya Raghunath Investing.com -- Mid-cap stocks are prime candidates for explosive growth. They are safer than small-caps but possess a lot more potential than large-caps. Here is a list...
-
Top 5 Mid-caps that Mutual Funds Bought and Sold in May
By Aditya Raghunath Investing.com -- Markets are entering a volatile space. It becomes necessary to identify the right stocks that can withstand this phase of the market. Here are the top 5...
-
2 Pharma Stocks that Can Give Up to 23% Returns: Motilal Oswal
By Aditya Raghunath Investing.com -- Brokerage firm Motilal Oswal Financial Services Ltd (NS:MOFS) has recommended a buy on two pharma stocks that it thinks can give returns of up to 23% in...
-
BRIEF-Jubilant Pharmova Completes Safety Studies For Novel Oral Formulation Of Remdesivir
April 19 (Reuters) - Jubilant Pharmova Ltd JUBA.NS :* COMPLETES SAFETY STUDIES IN ANIMALS, HEALTHY HUMANS IN INDIA USING NOVEL ORAL FORMULATION OF REMDESIVIR* HAS SOUGHT AUTHORIZATION FOR...
-
BRIEF-Jubilant Pharmova Says Arvind Chokhany Named Group CFO
April 1 (Reuters) - Jubilant Pharmova Ltd JUBA.NS :* JUBILANT PHARMOVA LTD - ARVIND CHOKHANY NAMED AS GROUP CFO
-
BRIEF-India's Jubilant Life Sciences Dec-Qtr Consol Net Profit Rises
Feb 5 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* DEC-QUARTER CONSOL NET PROFIT 3.1 BILLION RUPEES VERSUS 2.03 BILLION RUPEES YEAR AGO* DEC-QUARTER CONSOL TOTAL REVENUE FROM...
-
Rakesh Jhunjhunwala Bought Stake in These Two Companies in Q3
By Aditya Raghunath Investing.com -- Data from BSE showed that noted investor, Rakesh Jhunjhunwala bought shares of Tata Communications Limited (NS:TATA) in the third quarter of FY2021....
-
BRIEF-Jubilant Life Sciences Ltd - Issued Commercial Papers Of 900 Million Rupees
Nov 26 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* JUBILANT LIFE SCIENCES LTD - ISSUED COMMERCIAL PAPERS OF 900 MILLION RUPEES...
-
BRIEF-Jubilant Life Sciences Says Unit Enters Strategic Partnership With Sofie Biosciences
Nov 4 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* UNIT JUBILANT PHARMA ENTERED INTO STRATEGIC PARTNERSHIP WITH SOFIE BIOSCIENCES* UNDER DEAL, CO TO BUY 25% STAKE IN SOFIE BIOSCIENCES...
-
BRIEF-Jubilant Life Sciences To Issue Non-Convertible Debentures Of Up To 1 Bln Rupees
Nov 4 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* TO ISSUE NON-CONVERTIBLE DEBENTURES OF UP TO 1 BILLION RUPEES...
-
BRIEF-Jubilant Life Posts Lower Profit, Says Increased Remdesivir Output Capacity
Nov 4 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* SEPT-QUARTER CONSOL NET PROFIT 2.24 BILLION RUPEES VERSUS PROFIT 2.49 BILLION RUPEES YEAR AGO* CONSENSUS FORECAST FOR SEPT-QUARTER...
-
BRIEF-Jubilant Life Sciences Issues Commercial Papers Of 300 Mln Rupees
Oct 9 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* HAS ISSUED COMMERCIAL PAPERS OF 300 MILLION RUPEES ON OCT 9, 2020...
-
BRIEF-Jubilant Industries Says Approved Sale Of Land And Building Of Manufacturing Unit In Pune
Sept 4 (Reuters) - Jubilant Industries Ltd JUBL.NS :* JUBILANT INDUSTRIES LTD SAYS APPROVED SALE OF LAND AND BUILDING OF MANUFACTURING UNIT IN PUNE* JUBILANT INDUSTRIES - SALE FOR 123.5...
-
Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
BENGALURU, Aug 13 (Reuters) - Zydus Cadila CADI.NS on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following...
-
BRIEF-Navidea Signs Binding Framework For Commercialization Partnership With Jubilant Radiopharma
Aug 10 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* NAVIDEA BIOPHARMACEUTICALS SIGNS BINDING FRAMEWORK FOR COMMERCIALIZATION PARTNERSHIP WITH JUBILANT RADIOPHARMA* NAVIDEA...
-
Sun Pharma latest to sell COVID-19 drug favipiravir in India
BENGALURU, Aug 4 (Reuters) - India's Sun Pharmaceutical Industries Ltd SUN.NS said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to...
-
BRIEF-Jubilant Life Sciences Launches Remdesivir For Injection Under Brand Name 'JUBI-R'
Aug 3 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* JUBILANT LIFE SCIENCES LTD SAYS UNIT HAS LAUNCHED REMDESIVIR FOR INJECTION UNDER BRAND NAME 'JUBI-R'* JUBILANT LIFE SCIENCES LTD...
-
Mylan to launch generic remdesivir version in India at $64 per 100 mg vial
BENGALURU, July 6 (Reuters) - Drugmaker Mylan NV MYL.O said on Monday it would launch its generic version of Gilead Sciences Inc 's GILD.O COVID-19 treatment remdesivir in India this month...
-
India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug
(Adds Cipla 's statement) June 21 (Reuters) - India's drug regulator has given Hetero Labs and Cipla Ltd CIPL.NS the green light to manufacture and market their generic version of Gilead...
-
REFILE-India gives Hetero Labs approval to make Gilead's COVID-19 drug
(Corrects typo in third and fourth paragraphs)June 21 (Reuters) - India's drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead...
-
BRIEF-Jubilant Life Sciences Issues Commercial Papers Of 500 Mln Rupees
June 19 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* ISSUANCE OF COMMERCIAL PAPERS OF 500 MILLION RUPEES...
-
UPDATE 1-India's Zydus Cadila to make Gilead's potential COVID-19 drug remdesivir
(Adds background, company statement)BENGALURU, June 12 (Reuters) - Indian drugmaker Zydus Cadila CADI.NS said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc...
-
BRIEF-India's Jubilant Life Sciences Posts March-Quarter Consol Profit
May 29 (Reuters) - Jubilant Life Sciences Ltd JULS.NS :* MARCH-QUARTER CONSOL NET PROFIT 2.6 BILLION RUPEES VERSUS LOSS OF 992.9 MILLION RUPEES LAST YEAR* CONSENSUS FORECAST FOR...
-
Indian shares enjoy stimulus boost; details eyed
By Sachin RavikumarBENGALURU, May 13 (Reuters) - A surge in banking stocks helped Indian shares settle higher on Wednesday after the government unveiled 20 trillion rupees ($266 billion) in...
-
UPDATE 3-Gilead ties up with generic drugmakers for COVID-19 drug supply
(Adds details on Gilead's agreements)May 12 (Reuters) - Gilead Sciences Inc GILD.O said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India...
-
India's Jubilant signs licensing deal for Gilead's potential COVID-19 drug
May 12 (Reuters) - India's Jubilant Life Sciences Ltd JULS.NS said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc 's GILD.O experimental...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
